Literature DB >> 11461162

Insulin secretion as a determinant of pancreatic cancer risk.

M F McCarty1.   

Abstract

New epidemiology confirms that glucose intolerance is a risk factor for pancreatic cancer, and that this association cannot be accounted for by an adverse impact of early pancreatic cancer on beta cell function. Previous reports indicate that risk for pancreatic cancer is increased in adult-onset diabetics. Since streptozotocin diabetes inhibits carcinogen-mediated induction of pancreatic cancer in hamsters, the most reasonable interpretation of these findings is that insulin (or some other beta cell product) acts as a promoter for pancreatic carcinogenesis. This view is consistent with a report that human pancreatic adenocarcinomas express insulin receptors that can stimulate mitosis; an additional possibility is that high insulin levels indirectly promote pancreatic carcinogenesis by boosting effective IGF-I activity via hepatic actions. In international ecologic epidemiology, pancreatic cancer rates correlate tightly with dietary intake of animal products; this may reflect the fact that vegan diets are associated with low diurnal insulin secretion. There is also suggestive evidence that macrobiotic vegan diets, which are low in glycemic index, may increase mean survival time in pancreatic cancer. However, other types of diets associated with decreased postprandial insulin response, such as high-protein diets or 'Mediterranean' diets high in oleic acid, may also have the potential for pancreatic cancer prevention. The huge increases of age-adjusted pancreatic cancer mortality in Japan and among African-Americans during the last century imply that pancreatic cancer is substantially preventable; a low-insulin-response diet coupled with exercise training, weight control, and smoking avoidance, commendable for a great many other reasons, may slash pancreatic cancer mortality dramatically. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461162     DOI: 10.1054/mehy.2001.1316

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

Review 1.  The complexities of obesity and diabetes with the development and progression of pancreatic cancer.

Authors:  Bin Bao; Zhiwei Wang; Yiwei Li; Dejuan Kong; Shadan Ali; Sanjeev Banerjee; Aamir Ahmad; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-12-01

2.  Nutrients from fruit and vegetable consumption reduce the risk of pancreatic cancer.

Authors:  Rick J Jansen; Dennis P Robinson; Rachael Z Stolzenberg-Solomon; William R Bamlet; Mariza de Andrade; Ann L Oberg; Kari G Rabe; Kristin E Anderson; Janet E Olson; Rashmi Sinha; Gloria M Petersen
Journal:  J Gastrointest Cancer       Date:  2013-06

3.  Glycemic index, glycemic load, and the risk of pancreatic cancer among postmenopausal women in the women's health initiative observational study and clinical trial.

Authors:  M S Simon; J M Shikany; M L Neuhouser; T Rohan; K Nirmal; Y Cui; J Abrams
Journal:  Cancer Causes Control       Date:  2010-08-15       Impact factor: 2.506

4.  Cardiorespiratory fitness and digestive cancer mortality: findings from the aerobics center longitudinal study.

Authors:  J Brent Peel; Xuemei Sui; Charles E Matthews; Swann A Adams; James R Hébert; James W Hardin; Timothy S Church; Steven N Blair
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

5.  Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan).

Authors:  Alan A Arslan; Kathy J Helzlsouer; Charles Kooperberg; Xiao-Ou Shu; Emily Steplowski; H Bas Bueno-de-Mesquita; Charles S Fuchs; Myron D Gross; Eric J Jacobs; Andrea Z Lacroix; Gloria M Petersen; Rachael Z Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Laufey Amundadottir; William R Bamlet; Aurelio Barricarte; Sheila A Bingham; Heiner Boeing; Marie-Christine Boutron-Ruault; Julie E Buring; Stephen J Chanock; Sandra Clipp; J Michael Gaziano; Edward L Giovannucci; Susan E Hankinson; Patricia Hartge; Robert N Hoover; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Peter Kraft; Shannon M Lynch; Jonas Manjer; Joann E Manson; Anne McTiernan; Robert R McWilliams; Julie B Mendelsohn; Dominique S Michaud; Domenico Palli; Thomas E Rohan; Nadia Slimani; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Jarmo Virtamo; Brian M Wolpin; Kai Yu; Anne Zeleniuch-Jacquotte; Alpa V Patel
Journal:  Arch Intern Med       Date:  2010-05-10

Review 6.  Hyperinsulinemia in Obesity, Inflammation, and Cancer.

Authors:  Anni M Y Zhang; Elizabeth A Wellberg; Janel L Kopp; James D Johnson
Journal:  Diabetes Metab J       Date:  2021-03-29       Impact factor: 5.893

Review 7.  An overview of genetic polymorphisms and pancreatic cancer risk in molecular epidemiologic studies.

Authors:  Yingsong Lin; Kiyoko Yagyu; Naoto Egawa; Makoto Ueno; Mitsuru Mori; Haruhisa Nakao; Hiroshi Ishii; Kozue Nakamura; Kenji Wakai; Satoyo Hosono; Akiko Tamakoshi; Shogo Kikuchi
Journal:  J Epidemiol       Date:  2010-11-06       Impact factor: 3.211

8.  A prospective study of physical activity and the risk of pancreatic cancer among women (United States).

Authors:  Brook A Calton; Rachael Z Stolzenberg-Solomon; Steven C Moore; Arthur Schatzkin; Catherine Schairer; Demetrius Albanes; Michael F Leitzmann
Journal:  BMC Cancer       Date:  2008-02-28       Impact factor: 4.430

9.  DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.

Authors:  Carlos K H Wong; Kenneth K C Man; Esther W Y Chan; Tingting Wu; Emily T Y Tse; Ian C K Wong; Cindy L K Lam
Journal:  BMJ Open Diabetes Res Care       Date:  2020-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.